Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Shares Gap Down – Here’s What Happened

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $26.35, but opened at $23.95. Fresenius Medical Care AG & Co. KGaA shares last traded at $23.8210, with a volume of 503,964 shares trading hands.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on FMS shares. Bank of America lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 25th. Weiss Ratings raised Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Finally, Zacks Research raised Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $27.80.

Fresenius Medical Care AG & Co. KGaA Stock Performance

The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 0.44. The firm has a 50-day simple moving average of $26.08 and a two-hundred day simple moving average of $26.59. The company has a market capitalization of $14.13 billion, a price-to-earnings ratio of 19.80, a price-to-earnings-growth ratio of 0.64 and a beta of 0.92.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.The company had revenue of $5.54 billion during the quarter, compared to the consensus estimate of $5 billion. As a group, sell-side analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Wayfinding Financial LLC bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at approximately $25,000. Brooklyn Investment Group raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 424.5% in the 1st quarter. Brooklyn Investment Group now owns 1,285 shares of the company’s stock valued at $32,000 after acquiring an additional 1,040 shares in the last quarter. TD Waterhouse Canada Inc. bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at approximately $36,000. Atlantic Union Bankshares Corp bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at approximately $43,000. Finally, Hantz Financial Services Inc. raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 568.5% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock valued at $59,000 after acquiring an additional 1,768 shares in the last quarter. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.